By: Danielle Ternyila From: targetedonc.com In an interview with Targeted Oncology, Peter Schmid, MD, PhD, discussed the findings from the interim analysis for the phase III KEYNOTE-522 study, which added pembrolizumab to neoadjuvant chemotherapy in patients with early-stage triple-negative breast cancer. The randomized, phase III KEYNOTE-522 clinical trial evaluated the benefit of adding the immune checkpoint inhibitor pembrolizumab (Keytruda) to …
TNBC: Updated Efficacy Results From IMpassion130
Insights From: Tiffany A. Traina, MD, Memorial Sloan Kettering Cancer Center From: onclive.com The IMpassion130 study was a randomized trial of about 900 patients who had either locally advanced breast cancer with no prior therapy or first-line metastatic triple-negative breast cancer. Patients were randomized to either nab-paclitaxel alone or nab-paclitaxel plus atezolizumab. The primary end points of the study included …
Adjuvant I/O in TNBC
Insights: Sara M. Tolaney, MD, MPH From: onclive.com Very recently, we’ve seen some exciting data that came out from KEYNOTE-522, which looked at a preoperative trial of adding pembrolizumab to chemotherapy in patients with triple-negative breast cancer. In this trial, patients received chemotherapy with anthracycline, Cytoxan, taxane, and platinum and then were randomized to receive that chemo [chemotherapy] backbone with …
Immunotherapy improves outcome in high-risk, HER2-negative breast cancer
By: Megan Brooks From: reuters.com Adding the immune-checkpoint inhibitor durvalumab and the PARP inhibitor olaparib to standard neoadjuvant chemotherapy may improve outcome in women with high-risk, HER2-negative breast cancer, according to results of the I-SPY 2 trial. The benefit was apparent in both the hormone-receptor-positive (HR+) and triple-negative breast cancer (TNBC) subgroups. The I-SPY 2 study enrolled women with high-risk, …
Immunomedics’ Trodelvy wins FDA nod for triple-negative breast cancer
By: Randy Osborne From: bioworld.com Immunomedics Inc. gained accelerated FDA clearance for Trodelvy (sacituzumab govitecan-hziy) to treat patients with metastatic triple-negative breast cancer (TNBC) who have undergone at least two prior therapies. It’s the first antibody-drug conjugate (ADC) given the go-ahead specifically in relapsed/refractory TNBC and the first anti-Trop-2 ADC bound for the market. Trodelvy, which was granted breakthrough therapy …
Novel Protein Landscape Identified for Metaplastic Breast Cancer
By: Leah Lawrence From: cancertherapyadvisor.com A new study has attempted to identify several biomarkers associated with metaplastic breast carcinoma (MBC), a highly aggressive form of triple-negative breast cancer (TNBC). “Clinically, MBCs are more metastatic and chemoresistant than nonmetaplastic TNBC, with the spindle subtype reported to have the worst prognosis,” the researchers wrote. “This significant clinical challenge highlights the need to …
Tailoring treatment for triple-negative breast cancer
Source: University of Pennsylvania From: sciencedaily.com Triple-negative breast cancer is a particularly aggressive form of the disease with no specific treatment. Researchers discovered that, in contrast to many other cancer types, activation of the interferon gamma signaling contributes to disease progression and spread. The findings may help doctors choose a personalized treatment strategy for triple-negative breast cancer patients, depending on …
Research How Gilead’s blood cancer med Zydelig might also address triple-negative breast cancer
By: Angus Liu From: fiercebiotech.com Triple-negative breast cancer (TNBC) is hard to treat, because it lacks three common markers for drugs to target. Now, instead of going after the tumors directly, a research team led by the University of Sussex in the U.K. has found a target in their surrounding environment and identified an existing blood cancer med as a …
Pembrolizumab improves treatment of patients with triple-negative breast cancer
By: Albina Babu From: medicalnewsbulletin.com A randomized phase 3 clinical trial has shown that pembrolizumab combined with chemotherapy improves the pathological complete response (defined as no evidence of cancer) of patients with early-stage triple-negative breast cancer. Triple-negative breast cancer (TNBC) is a high-risk cancer type comprising approximately 15% of all breast cancers. However, TNBC is more aggressive and has higher …
Study Says Combination of MEK, BET Inhibitors May be Effective in Portion of Breast Cancer Patients
By: Staff Reporter By: precisiononcologynews.com A new study published in Science Translational Medicine this week found that MET inhibitors in combination with BET inhibitors could be potent against high MYCN-expressing triple negative breast cancer. The authors of the study hope that their findings will accelerate development of BET inhibitors for TNBC, where there is an unmet need. TNBC accounts for …